Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.
Jung S, Nelde A, Maringer Y, Denk M, Zieschang L, Kammer C, Özbek M, Martus P, Hackenbruch C, Englisch A, Heitmann JS, Salih HR, Walz JS. Jung S, et al. Among authors: hackenbruch c. Front Oncol. 2024 Oct 14;14:1458449. doi: 10.3389/fonc.2024.1458449. eCollection 2024. Front Oncol. 2024. PMID: 39469638 Free PMC article.
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.
Englisch A, Hayn C, Jung S, Heitmann JS, Hackenbruch C, Maringer Y, Nelde A, Wacker M, Denk M, Zieschang L, Kammer C, Martus P, Salih HR, Walz JS. Englisch A, et al. Among authors: hackenbruch c. Front Oncol. 2024 Aug 26;14:1441625. doi: 10.3389/fonc.2024.1441625. eCollection 2024. Front Oncol. 2024. PMID: 39252947 Free PMC article.
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
Hackenbruch C, Bauer J, Heitmann JS, Maringer Y, Nelde A, Denk M, Zieschang L, Kammer C, Federmann B, Jung S, Martus P, Malek NP, Nikolaou K, Salih HR, Bitzer M, Walz JS. Hackenbruch C, et al. Front Oncol. 2024 Mar 28;14:1367450. doi: 10.3389/fonc.2024.1367450. eCollection 2024. Front Oncol. 2024. PMID: 38606105 Free PMC article.
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3).
Jung S, Schlenk RF, Hackenbruch C, Roldan Pinzon SSL, Bitzer M, Pflügler M, Walz JS, Jung G, Heitmann JS, Salih HR. Jung S, et al. Among authors: hackenbruch c. Front Oncol. 2024 Feb 12;14:1351901. doi: 10.3389/fonc.2024.1351901. eCollection 2024. Front Oncol. 2024. PMID: 38410109 Free PMC article.
Isolation of T cells from the gut.
Reißig S, Hackenbruch C, Hövelmeyer N. Reißig S, et al. Among authors: hackenbruch c. Methods Mol Biol. 2014;1193:21-5. doi: 10.1007/978-1-4939-1212-4_3. Methods Mol Biol. 2014. PMID: 25150993